A New Dawn in Glioblastoma's Shadow: FDA Greenlights Pioneering Human Trial

Myosin Therapeutics gains FDA clearance for first-in-human trials of MT-125, a novel drug targeting aggressive glioblastoma.
MT-125 offers a new strategy against a notoriously treatment-resistant cancer, particularly for patients with poor prognoses due to MGMT unmethylated tumors.
The drug targets non-muscle myosin II (NMII), aiming to disrupt tumor growth, invasion, and therapy resistance.

In a significant stride against one of oncology's most formidable adversaries, Myosin Therapeutics today announced a beacon of hope: FDA clearance to begin human trials for MT-125. This groundbreaking drug candidate takes aim at glioblastoma, an aggressive brain cancer that has seen tragically few treatment advances in decades, especially for patients with IDH wild-type, MGMT unmethylated tumors who face a particularly grim outlook^{1, 6, 7}.

Founded in 2020 by a team from Scripps Research, Myosin Therapeutics, based in Jupiter, FL, is pioneering therapies targeting molecular motors⁸. Their lead candidate, MT-125, is a first-in-class selective inhibitor of non-muscle myosin II (NMII). This molecular motor is a key driver of tumor proliferation, invasion, therapy resistance, and even immune evasion^{1, 7}. By neutralizing NMII, MT-125 aims to dismantle glioblastoma's deadly machinery from within.

Preclinical studies have already painted a promising picture, showing MT-125's potent anti-tumor activity and its ability to enhance radiotherapy's effects^{1, 7}. "Glioblastoma remains one of the most aggressive and treatment-resistant cancers," stated Dr. Courtney Miller, Founder and CEO. "We're driven and encouraged by the FDA's clearance...Preclinical studies suggest targeting non-muscle myosin II represents a uniquely holistic approach to tackling this complex and devastating disease"¹.

This pivotal moment allows Myosin to initiate a Phase 1 study in collaboration with the Mayo Clinic, evaluating MT-125 with standard radiation for newly diagnosed patients¹. The FDA has already granted MT-125 Orphan Drug Designation, acknowledging its potential against this rare and devastating disease and providing crucial support^{1, 7}. With funding from the National Cancer Institute bolstering its development⁸, MT-125 represents a new offensive in a long and arduous battle, offering a glimmer of light for patients in desperate need of new options¹.

A New Dawn in Glioblastoma's Shadow: FDA Greenlights Pioneering Human Trial

References

Stay Updated!